<https://helda.helsinki.fi>

Common variants in breast cancer risk loci predispose to distinct tumor subtypes

NBCS Collaborators

2022-01-04

NBCS Collaborators , ABCTB Investigators , kConFab-AOCS Investigators , Ahearn , T U , Zhang , H , Michailidou , K , Blomqvist , C & Nevanlinna , H 2022 , ' Common variants in breast cancer risk loci predispose to distinct tumor subtypes ' , Breast Cancer Research , vol. 24 , no. 1 , 2 . <https://doi.org/10.1186/s13058-021-01484-x>

<http://hdl.handle.net/10138/338911>

<https://doi.org/10.1186/s13058-021-01484-x>

cc_by

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

RESEARCH ARTICLE

Open Access

Common variants in breast cancer risk loci predispose to distinct tumor subtypes

Thomas U. Ahearn^{1†} , Haoyu Zhang^{1,2†}, Kyriaki Michailidou^{3,4,5}, Roger L. Milne^{6,7,8}, Manjeet K. Bolla⁴, Joe Dennis⁴, Alison M. Dunning⁹, Michael Lush⁴, Qin Wang⁴, Irene L. Andrulis^{10,11}, Hoda Anton-Culver¹², Volker Arndt¹³, Kristan J. Aronson¹⁴, Paul L. Auer^{15,16}, Annelie Augustinsson¹⁷, Adinda Baten¹⁸, Heiko Becher¹⁹, Sabine Behrens²⁰, Javier Benitez^{21,22}, Marina Bermisheva^{23,24}, Carl Blomqvist^{25,26}, Stig E. Bojesen^{27,28,29}, Bernardo Bonanni³⁰, Anne-Lise Børresen-Dale^{31,32}, Hiltrud Brauch^{33,34,35}, Hermann Brenner^{13,36,37}, Angela Brooks-Wilson^{38,39}, Thomas Brüning⁴⁰, Barbara Burwinkel^{41,42}, Sandra S. Buys⁴³, Federico Canzian⁴⁴, Jose E. Castelao⁴⁵, Jenny Chang-Claude^{20,46}, Stephen J. Chanock¹, Georgia Chenevix-Trench⁴⁷, Christine L. Clarke⁴⁸, NBCS Collaborators, J. Margriet Collée⁴⁹, Angela Cox⁵⁰, Simon S. Cross⁵¹, Kamila Czene⁵², Mary B. Daly⁵³, Peter Devilee^{54,55}, Thilo Dörk⁵⁶, Miriam Dwek⁵⁷, Diana M. Eccles⁵⁸, D. Gareth Evans^{59,60}, Peter A. Fasching⁶¹, Jonine Figueroa^{62,63}, Giuseppe Floris¹⁸, Manuela Gago-Dominguez^{64,65}, Susan M. Gapstur⁶⁶, José A. García-Sáenz⁶⁷, Mia M. Gaudet⁶⁶, Graham G. Giles^{6,7,8}, Mark S. Goldberg^{68,69}, Anna González-Neira²¹, Grethe I. Grenaker Alnæs³¹, Mervi Grip⁷⁰, Pascal Guénel⁷¹, Christopher A. Haiman⁷², Per Hall^{52,73}, Ute Hamann⁷⁴, Elaine F. Harkness^{75,76,77}, Bernadette A. M. Heemskerk-Gerritsen⁷⁸, Bernd Holleczek⁷⁹, Antoinette Hollestelle⁷⁸, Maartje J. Hoening⁷⁸, Robert N. Hoover¹, John L. Hopper⁷, Anthony Howell⁸⁰, ABCTB Investigators, kConFab/AOCS Investigators, Milena Jakimovska⁸¹, Anna Jakubowska^{82,83}, Esther M. John^{84,85}, Michael E. Jones⁸⁶, Audrey Jung²⁰, Rudolf Kaaks²⁰, Saila Kauppila⁸⁷, Renske Keeman⁸⁸, Elza Khusnutdinova^{89,23}, Cari M. Kitahara⁹⁰, Yon-Dschun Ko⁹¹, Stella Koutros¹, Vessela N. Kristensen^{32,92}, Ute Krüger¹⁷, Katerina Kubelka-Sabit⁹³, Allison W. Kurian^{84,85}, Kyriacos Kyriacou^{94,5}, Diether Lambrechts^{95,96}, Derrick G. Lee^{97,98}, Annika Lindblom^{99,100}, Martha Linet⁹⁰, Jolanta Lissowska¹⁰¹, Ana Llana¹⁰², Wing-Yee Lo^{33,103}, Robert J. MacInnis^{6,7}, Arto Mannermaa^{104,105,106}, Mehdi Manoochehri⁷⁴, Sara Margolin^{73,107}, Maria Elena Martinez⁶⁵, Catriona McLean¹⁰⁸, Alfons Meindl¹⁰⁹, Usha Menon¹¹⁰, Heli Nevanlinna¹¹¹, William G. Newman^{59,60}, Jesse Nodora^{65,112}, Kenneth Offit¹¹³, Håkan Olsson¹⁷, Nick Orr¹¹⁴, Tjong-Won Park-Simon⁵⁶, Alpa V. Patel⁶⁶, Julian Peto¹¹⁵, Guillermo Pita¹¹⁶, Dijana Plaseska-Karanfilska⁸¹, Ross Prentice¹⁵, Kevin Punie¹¹⁷, Katri Pylkäs^{118,119}, Paolo Radice¹²⁰, Gad Rennert¹²¹, Atocha Romero¹²², Thomas Rüdiger¹²³, Emmanouil Saloustros¹²⁴, Sarah Sampson¹²⁵, Dale P. Sandler¹²⁶, Elinor J. Sawyer¹²⁷, Rita K. Schmutzler^{128,129,130}, Minouk J. Schoemaker⁸⁶, Ben Schöttker^{13,131}, Mark E. Sherman¹³², Xiao-Ou Shu¹³³, Snezhana Smichkoska¹³⁴, Melissa C. Southey^{6,135,8}, John J. Spinelli^{136,137}, Anthony J. Swerdlow^{86,138}, Rulla M. Tamimi¹³⁹, William J. Tapper⁵⁸, Jack A. Taylor^{126,140}, Lauren R. Teras⁶⁶, Mary Beth Terry¹⁴¹, Diana Torres^{142,74}, Melissa A. Troester¹⁴³, Celine M. Vachon¹⁴⁴

*Correspondence: montserrat.garcia-closas@nih.gov

[†]Thomas U. Ahearn, Haoyu Zhang, Montserrat García-Closas, and Nilanjan Chatterjee have contributed equally to this work

¹ Division of Cancer Epidemiology and Genetics Department of Health and Human Services, Medical Center Drive, National Cancer Institute, National Institutes of Health, Rockville, MD, USA

Full list of author information is available at the end of the article

© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Carolien H. M. van Deurzen¹⁴⁵, Elke M. van Veen^{59,60}, Philippe Wagner¹⁷, Clarice R. Weinberg¹⁴⁶, Camilla Wendt^{73,107}, Jelle Wesseling^{88,147}, Robert Winqvist^{118,119}, Alicja Wolk^{148,149}, Xiaohong R. Yang¹, Wei Zheng¹³³, Fergus J. Couch¹⁵⁰, Jacques Simard¹⁵¹, Peter Kraft^{152,153}, Douglas F. Easton^{9,4}, Paul D. P. Pharoah^{9,4}, Marjanka K. Schmidt^{88,154}, Montserrat García-Closas^{1*†} and Nilanjan Chatterjee^{155,156†}

Abstract

Background: Genome-wide association studies (GWAS) have identified multiple common breast cancer susceptibility variants. Many of these variants have differential associations by estrogen receptor (ER) status, but how these variants relate with other tumor features and intrinsic molecular subtypes is unclear.

Methods: Among 106,571 invasive breast cancer cases and 95,762 controls of European ancestry with data on 173 breast cancer variants identified in previous GWAS, we used novel two-stage polytomous logistic regression models to evaluate variants in relation to multiple tumor features (ER, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and grade) adjusting for each other, and to intrinsic-like subtypes.

Results: Eighty-five of 173 variants were associated with at least one tumor feature (false discovery rate < 5%), most commonly ER and grade, followed by PR and HER2. Models for intrinsic-like subtypes found nearly all of these variants (83 of 85) associated at $p < 0.05$ with risk for at least one luminal-like subtype, and approximately half (41 of 85) of the variants were associated with risk of at least one non-luminal subtype, including 32 variants associated with triple-negative (TN) disease. Ten variants were associated with risk of all subtypes in different magnitude. Five variants were associated with risk of luminal A-like and TN subtypes in opposite directions.

Conclusion: This report demonstrates a high level of complexity in the etiology heterogeneity of breast cancer susceptibility variants and can inform investigations of subtype-specific risk prediction.

Keywords: Breast cancer, Etiologic heterogeneity, Genetic predisposition, Common breast cancer susceptibility variants

Introduction

Breast cancer represents a heterogeneous group of diseases with different molecular and clinical features[1]. Clinical assessment of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and histological grade are routinely determined to inform treatment strategies and prognostication[2]. Combined, these tumor features define five intrinsic-like subtypes (i.e., luminal A-like, luminal B-like/HER2-negative, luminal B-like/HER2-positive, HER2-positive/non-luminal, and triple-negative) that are correlated with intrinsic subtypes defined by gene expression panels[2, 3]. Most known breast cancer risk or protective factors are related to luminal or hormone receptor (ER or PR) positive tumors, whereas less is known about the etiology of triple-negative (TN) tumors, an aggressive subtype[4, 5].

Breast cancer genome-wide association studies (GWAS) have identified over 170 common susceptibility variants, most of them single nucleotide polymorphisms (SNPs), of which many are differentially associated with ER-positive than ER-negative disease[6–8]. These include 20 variants that primarily predispose to ER-negative or TN disease[7, 8]. However, few studies have evaluated

variant associations with other tumor features, or simultaneously studied multiple, correlated tumor markers to identify source(s) of etiologic heterogeneity[7, 9–13]. We recently developed a two-stage polytomous logistic regression method that efficiently characterizes etiologic heterogeneity while accounting for tumor marker correlations and missing tumor data[14, 15]. This method can help describe complex relationships between susceptibility variants and multiple tumor features, helping to clarify breast cancer subtype etiologies and increasing the power to generate more accurate risk estimates between susceptibility variants and less common subtypes. We recently demonstrated the power of this method in a GWAS to identify novel breast cancer susceptibility accounting for tumor heterogeneity[15].

In this report, we sought to expand our understanding of etiologic heterogeneity across breast cancer subtypes, by applying the two-stage polytomous logistic regression methodology to a large study population from the Breast Cancer Association Consortium (BCAC) for detailed characterization of risk associations with 173 breast cancer risk variants identified by GWAS[6, 7] by tumor subtypes defined by ER, PR, HER2 and tumor grade.

Methods

Study population and genotyping

The study population and genotyping are described in previous publications[6, 7] and in the Additional file 3: Methods. We included invasive cases and controls from 81 BCAC studies with genotyping data from two Illumina genome-wide custom arrays, the iCOGS and OncoArray (106,571 cases (OncoArray: 71,788; iCOGS: 34,783) and 95,762 controls (OncoArray: 58,134; iCOGS: 37,628); Additional file 1: Table S1). All subjects in the study population were female and of European ancestry, with European ancestry determined by ancestry informative GWAS markers as previously described [6]. We evaluated 173 breast cancer risk variants that were identified in or replicated by prior BCAC analyses to be associated with breast cancer risk at a p-value threshold $p < 5.0 \times 10^{-8}$ [6, 7]. Most of these variants ($n=153$) were identified because of their association with risk of overall breast cancer, and a small number of variants ($n=20$) were identified because of their association specific to ER-negative breast cancer (Additional file 1: Table S2). These 173 variants have not previously been simultaneously investigated for evidence of tumor heterogeneity with multiple tumor markers[6, 7, 15, 16]. Genotypes for the variants marking the 173 susceptibility loci were determined by genotyping with the iCOGS and the OncoArray arrays and imputation to the 1000 Genomes Project (Phase 3) reference panel.

Statistical analysis

An overview of the analytic strategy is shown in Fig. 1 and a detailed discussion of the statistical methods, including the two-stage polytomous logistic regression, are provided in the Additional file 3: Methods and elsewhere[14, 15]. Briefly, we used two-stage polytomous regression models that allow modelling of genetic association of breast cancer accounting for underlying heterogeneity in associations by combinations of multiple tumor markers using a parsimonious decomposition of subtype-specific case-control odds-ratio parameters in terms of marker-specific case-case odd-ratio parameters[14, 15]. We introduced further parsimony by using the mixed-effect formulation of the model that allows ER-specific case-case parameters to be treated as fixed and similar parameters for other markers (PR, HER2 and grade (as an ordinal variable)) as random. We used an expectation-maximization (EM) algorithm[17] for parameter estimation under this model to account for missing data in tumor characteristics.

Our primary aim was to identify which of 173 known breast cancer susceptibility variants showed heterogeneous risk associations by ER-, PR- and HER2-status and tumor grade. This was tested using a global heterogeneity

test by ER, PR, HER2 and/or grade, with a mixed-effect two-stage polytomous model (model 1), fitted separately for each variant. The global null hypothesis was that there was no difference in risk of breast cancer associated with the variant genotype across any of the tumor features being evaluated. We accounted for multiple testing (173 tests, one for each variant) of the global heterogeneity test using a false discovery rate (FDR) < 5% under the Benjamini-Hochberg procedure[18].

For the variants showing evidence of global heterogeneity after FDR adjustment, we further evaluated which of the tumor features contributed to the heterogeneity by fitting a fixed-effects two-stage model (model 2) that simultaneously tested for associations with each tumor feature (this model was fitted for each variant separately). We used a threshold of $p < 0.05$ for marker-specific tumor heterogeneity tests to describe which specific tumor marker(s) contributed to the observed heterogeneity, adjusting for the other tumor markers in the model. This p-value threshold was used only for descriptive purposes, as the primary hypotheses were tested using the FDR-adjusted global test for heterogeneity described above.

We conducted additional analyses to explore for evidence of heterogeneity. We fitted a fixed-effect two-stage model (model 3) to estimate case-control odd ratios (ORs) and 95% confidence intervals (CI) between the variants and five intrinsic-like subtypes defined by combinations of ER, PR, HER2 and grade: (1) luminal A-like (ER+ and/or PR+, HER2-, grade 1 or 2); (2) luminal B-like/HER2-negative (ER+ and/or PR+, HER2-, grade 3); (3) luminal B-like/HER2-positive (ER+ and/or PR+, HER2+); (4) HER2-positive/non-luminal (ER- and PR-, HER2+), and (5) TN (ER-, PR-, HER2-). We also fitted a fixed-effect two-stage model to estimate case-control ORs and 95% confidence intervals (CI) with tumor grade (model 4; defined ordinally as grade 1, grade 2, and grade 3) for the variants associated at $p < 0.05$ only with grade in case-case comparisons from model 2.

To help describe sources of heterogeneity from different tumor characteristics in models 2 and 3, we performed cluster analyses based on Euclidean distance calculated from the absolute z-statistics that were estimated by the individual marker-specific tumor heterogeneity tests (model 2) and the case-control associations with risk of intrinsic-like subtypes (model 3). The clusters were used only for presentation purposes and were not intended to suggest strictly defined categories, nor are they intended to suggest the variants are associated with tumor markers through similar biological mechanisms. Clustering was performed in R using the function Heatmap as implemented by the package “Complex Heatmap” version 3.1[19]. Additional details for calculating

Fig. 1 Overview of the analytic strategy and results from the investigation of 173 known breast cancer susceptibility variants for evidence of heterogeneity of effect according to the estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and grade. ^aWe evaluated 173 breast cancer risk variants identified in or replicated by prior BCAC GWAS [6, 7], see [Methods](#) and [Additional file 3: Methods](#) sections for more details. ^bModel 1 (primary analyses): Mixed-effect two-stage polytomous model (ER as fixed-effect, and PR, HER2 and grade as random-effects) for [global heterogeneity tests](#) (i.e. case-case comparisons from stage 2 of the two-stage model) between each individual risk variant and any of the tumor features (separate models were fit for each variant). ^cModel 2: Fixed-effect two-stage polytomous model for [marker-specific tumor heterogeneity tests](#) (i.e. case-case comparisons from stage 2 of the two-stage model) between each individual variant and each of the tumor features (ER, PR, HER2, and grade), mutually adjusted for each other (separate models were fit for each variant). ^dModel 3: Fixed effect two-stage polytomous model for [risk associations with intrinsic-like subtypes](#) (i.e. case-control comparisons from stage 1 of the two-stage model): luminal A-like, luminal B-like/HER2-negative, luminal B-like/HER2-positive, HER2-positive/non-luminal, and triple-negative. ^eModel 4: Fixed effect two-stage polytomous model for [risk associations with tumor grade](#) (i.e. case-control comparisons from stage 1 of the two-stage model) for the 12 variants associated at $p < 0.05$ only with grade in case-case comparisons (from model 2): grade 1, grade 2, and grade 3

Euclidean distance using absolute z-statistics are provided in [Additional file 3: Methods](#).

We performed sensitivity analyses, in which we estimated the ORs and 95% CI between the variants and the intrinsic-like subtypes by implementing a standard polytomous model that defined the intrinsic-like subtypes using only the available tumor markers data (not using the EM algorithm to account for missing data in tumor markers). We analyzed OncoArray and iCOGS array data separately for all analyses, adjusting for the first ten principal components for ancestry-informative variants, and then meta-analyzed the results.

Results

The mean (SD) ages at diagnosis (cases) and enrollment (controls) were 56.6 (12.2) and 56.4 (12.2) years, respectively. Among cases with information on the corresponding tumor marker, 81% were ER-positive, 68%

PR-positive, 83% HER2-negative and 69% grade 1 or 2 ([Table 1](#); see [Additional file 1: Table S1](#) for details by study). [Additional file 1: Table S3](#) shows the correlation between the tumor markers. ER was positively correlated with PR ($r = 0.61$) and inversely correlated with HER2 ($r = -0.16$) and grade ($r = -0.39$). The most common intrinsic-like subtype was luminal A-like (54%), followed by TN (14%), luminal B-like/HER2-negative (13%), Luminal B-like/HER2-positive (13%) and HER2-positive/non-luminal (6%; [Table 1](#)). These frequencies varied across BCAC studies because the studies were diverse in both design and country of origin ([Additional file 1: Table S1](#)). Notably, there is little population-based data on the frequencies of intrinsic-like subtypes [20, 21]. The overall frequencies in our study population are generally similar to those reported by SEER for non-Hispanic white females and the Scottish cancer registry [20, 21]; however, given the diverse sources of our data,

they are not directly comparable to country-specific cancer registries.

Figure 1 shows an overview of the analytic strategy and results from three main analyses performed separately for each variant: 1) global test for heterogeneity by all tumor markers (model 1; primary hypothesis), 2) marker-specific tumor test for heterogeneity for each marker, adjusting for the others (model 2), and 3) estimation of case-control ORs (95% CIs) by intrinsic-like subtypes (model 3) and by grade (model 4).

Global test for heterogeneity by tumor markers (primary hypothesis)

Mixed-effects two-stage models (model 1) were fitted for each of the 173 variants separately and included terms for ER, PR, HER2 and grade to test for global heterogeneity by any of the tumor features (case-case comparison). This model identified 85 of 173 (49.1%) variants with evidence of heterogeneity by at least one tumor feature ($FDR < 5\%$; Figs. 1, 2; Additional file 1: Fig. S1).

Marker-specific tumor test for heterogeneity for each marker, adjusting for other markers

Fixed-effects two-stage models (model 2) were used to test which of the correlated tumor markers was responsible for the observed global heterogeneity (case-case comparison). Figure 2 and Additional file 1: Fig. S1 show results of these analyses clustered by case-case z-values of associations between susceptibility variants and each tumor marker for the 173 variants. For the 85 variants with observed global heterogeneity, these analyses identified ER and grade as the two features that most often

contributed to the observed heterogeneity (45 and 33 variants had marker-specific $p < 0.05$ for ER and grade, respectively), and 29 variants were associated with more than one tumor feature (Figs. 1, 2, Additional file 1: Fig. S1). Eighteen of these 85 variants showed no associations with any individual tumor marker at $p < 0.05$ (Fig. 2, Additional file 1: Fig. S1). Twenty-one variants were associated at $p < 0.05$ only with ER, 12 variants only with grade, four variants only with PR and one variant only with HER2 (Fig. 2, Additional file 1: Fig. S1, see footnotes).

Estimation of case-control ORs (95% CIs) by intrinsic-like subtypes (model 3)

Fixed-effects two-stage models for intrinsic-like subtypes (model 3) were fitted for each of the 85 variants with evidence of global heterogeneity to estimate ORs (95% CIs) for risk associations with each subtype (case-control comparisons). Additional file 1: Fig. S2 shows a summary of these analyses for the 85 variants, clustered by case-control z-value of association between susceptibility variants and breast cancer intrinsic-like subtypes, and Additional file 2: Fig. S3 shows forest plots for associations with risk by tumor subtypes. Nearly all (83 of 85) variants were associated with risk ($p < 0.05$) for at least one luminal-like subtype, and approximately half (41 of 85) of the variants were associated with risk of at least one non-luminal subtype, including 32 variants that were associated with risk of TN disease (Fig. 1, Additional file 1: Fig. S2 footnote 'h'). Ten variants were associated with risk of all subtypes (Fig. 1, Additional file 1: Fig. S2 footnote 'j'). Below we describe examples of groups of

^a Per-minor allele odds ratio (95% confidence limits).
^b Model 1, mixed-effects two-stage polytomous model testing for global heterogeneity according to estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and grade
^c Predicted target genes as reported in Fachal L, et al. Nature genetics 2020; 52 (1), 56-73
^d Luminal A-like (ER+ and/or PR+, HER2-, grade 1 & 2); Luminal B-like/HER2-negative (ER+ and/or PR+, HER2-, grade 3); luminal B-like/HER2-positive (ER+ and/or PR+, HER2+); HER2-positive/non-luminal (ER- and PR-, HER2+), and triple-negative (ER-, PR-, HER2-)
Fig. 3 Results from fixed-effects two-stage polytomous models for risk associations^a with intrinsic-like subtypes (model 3) for variants with evidence of heterogeneity by tumor markers in the two-stage model (model1)^b; panels show examples of variants **(a)** most strongly associated with luminal-like subtypes, **(b)** most strongly associated with TN subtypes, **(c)** associated with all subtypes with varying strengths of association, and **(d)** associated with luminal A-like and TN subtypes in different directions. See Additional file 1: Fig. S2 for more details

variants associated with different patterns of associations with intrinsic subtypes (Fig. 3 a-d). Two variants in linkage disequilibrium (LD, $r^2=0.73$) at 10q26.13 (rs2981578 and rs35054928) and 16q12.1-rs4784227 had the strongest evidence of association with risk of luminal-like subtypes (Fig. 3a, Additional file 1: Fig. S2). The two variants at 10q26.13 showed no evidence of associations with TN subtypes, and a weaker association with HER2-positive/non-luminal subtype. In contrast, 16q12.1-rs4784227 was strongly associated

with risk of all luminal-like subtypes and, weaker so, with risk of HER2-positive/non-luminal and TN subtypes (Figs. 3a, Additional file 1: Fig. S2). Three variants 19p13.11-rs67397200, 5p15.33-rs10069690 and 1q32.11-rs4245739 showed the strongest evidence of associations with risk of TN disease. All three of these variants showed weaker or no evidence of associations with risk of the other subtypes (Fig. 3b, Additional file 1: Fig. S2).

Table 1 Distribution of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and grade and the intrinsic-like subtypes for cases of invasive breast cancer in studies from the Breast Cancer Consortium Association

Tumor marker	N (%)
ER	
Negative	16,900 (19%)
Positive	70,030 (81%)
Unknown	19,641
PR	
Negative	24,283 (32%)
Positive	51,603 (68%)
Unknown	30,685
HER2	
Negative	47,693 (83%)
Positive	9,529 (17%)
Unknown	49,349
Grade	
1	15,583 (20%)
2	37,568 (49%)
3	24,382 (31%)
Unknown	29,038
Intrinsic-like subtypes	
Luminal A-like	27,510 (54%)
Luminal B-like/HER2-negative	6,804 (13%)
Luminal B-like/HER2-positive	6,511 (13%)
HER2-positive/non-luminal	2,797 (6%)
Triple-negative	7,178 (14%)
Unknown	55,771

Luminal A-like (ER + and/or PR +, HER2-, grade 1 & 2); Luminal B-like/HER2-negative (ER + and/or PR +, HER2-, grade 3); Luminal B-like/HER2-positive (ER + and/or PR +, HER2+); HER2-positive/non-luminal (ER- and PR-, HER2 +), and triple-negative (ER-, PR-, HER2-)

Two variants in low LD ($r^2=0.17$) at 6q25, rs9397437 and rs3757322, and a third variant in 6q25, rs2747652, which was not in LD ($r^2<0.01$) with rs9397437 or rs3757322, showed strong evidence of being associated with risk of all subtypes. rs9397437 and rs3757322 were most strongly associated with risk of TN disease. rs2747652 was most strongly associated with risk of HER2-positive subtypes (Figs. 3c, Additional file 1: Fig. S2).

Five variants were associated with risk of luminal A-like disease in an opposite direction to their association with risk of TN disease. 1q32.1-rs6678914, 2p23.2-rs4577244, and 19p13.11-rs67397200 had weaker evidence of associations with risk of luminal A-like disease compared to associations with risk of TN disease, and 10p12.31-rs7072776 and 22q12.1-rs17879961 (I157T) had stronger evidence of an association with risk of luminal A-like disease compared to their association with risk of TN

disease (Fig. 3d, Additional file 1: Fig. S2, for rs67397200 see Fig. 3b).

Estimation of case-control ORs (95%CI) by tumor grade (model 4)

Case-control associations by tumor grade for the 12 variants that were observed associated at $p<0.05$ only with grade in case-case comparisons are shown in Additional file 2: Fig. S4. 13q13.1-rs11571833, 1p22.3-rs17426269 and 11q24.3-rs11820646 showed stronger evidence for predisposing to risk of high-grade subtypes, and the remaining variants showed stronger evidence for predisposing to risk of low-grade subtypes.

When limiting analyses to cases with intrinsic-like subtypes defined only by available tumor marker data, results from case-control analyses were similar, but less precise than results from the two-stage polytomous regression model using the EM algorithm to account for missing tumor marker data (Additional file 1: Table S4).

Discussion

This study demonstrates the extent and complexity of genetic etiologic heterogeneity among 173 breast cancer risk variants by multiple tumor characteristics, using novel methodology in the largest and the most comprehensive investigation conducted to date. We found compelling evidence that about half of the investigated breast cancer susceptibility loci (85 of 173 variants) predispose to tumors with different characteristics. We identified tumor grade, along with confirming ER status, as important determinants of etiologic heterogeneity. Associations with individual tumor features translated into differential associations with the risk of intrinsic-like subtypes defined by their combinations.

Many of the variants with evidence of global heterogeneity predisposed to risk of multiple subtypes, but with different magnitudes. For example, three variants identified in early GWAS for overall breast cancer, *FGFR2* (rs35054928 and rs2981578)[22, 23] and 8q24.21 (rs13281615)[22], were associated with luminal-like and HER2-positive/non-luminal subtypes, but not with TN disease. rs4784227 located near *TOX3*[22, 24] and rs62355902 located in a *MAP3KI*[22] regulatory element, were associated with risk of all five subtypes. Of the five variants found associated in opposite directions with luminal A-like and TN disease, we previously reported rs6678914 and rs4577244 to have opposite effects between ER-negative and ER-positive tumors[7]. rs17879961 (I157T), a likely causal[16] missense variant located in a *CHEK2* functional domain that reduces or abolishes substrate binding[25], was previously reported to have opposite directions of effects on lung adenocarcinoma and lung squamous cell carcinoma and for

lung cancer between smokers and non-smokers[26, 27]. Moreover, the risk association of rs17879961 has been reported to vary across tissue locations/cell-types, as this variant has been associated with a higher risk of pancreatic ductal adenocarcinoma [28], chronic lymphocytic leukemia [29], and colorectal cancer [30], and also associated with a lower risk of aerodigestive squamous cell carcinoma [31] and ovarian cancer [32]. To our knowledge, rs67397200 and rs7072776 have not previously been shown to be associated with subtypes in opposite directions. In a prior breast cancer GWAS that applied the two-stage polytomous model for risk variant discovery, we also identified five variants associated with risk of luminal A-like and TN disease in opposite directions [15]. Overall, these findings suggest that the same biological pathway has opposite effects on the susceptibility to different tumor types. This interpretation is supported by functional characterization of rs36115365, a variant on 5p15.33, which was found to have similar cis-regulatory effects on TERT in multiple cancers cell lines from different cancers, but was associated with a higher risk of pancreatic and testicular cancer and a lower risk of lung cancer [33]. Alternatively, a causal variant may differently influence cis-gene regulation and/or alter different biological pathways depending on the cell or tissue of origin [34]. Further studies of these variants are required to clarify the biological mechanisms for these apparent cross-over effects.

In prior ER-negative GWAS, we identified 20 variants that predispose to ER-negative disease, of which five variants were only or most strongly associated with risk of TN disease (rs4245739, rs10069690, rs74911261, rs11374964, and rs67397200)[7, 8]. We confirmed these five variants to be most strongly associated with TN disease. The remaining previously identified 15 variants all showed associations with risk of non-luminal subtypes, especially TN disease, and for all but four variants (rs17350191, rs200648189, rs6569648, and rs322144), evidence of global heterogeneity was observed.

Little is known regarding PR and HER2 as sources of etiologic heterogeneity independent of ER status. Of the four variants that showed evidence of heterogeneity only according to PR, rs10759243[6, 35], rs11199914[36] and rs72749841[6] were previously found primarily associated with risk of ER-positive disease, and rs10816625 was found to be associated with risk of ER-positive/PR-positive tumors, but not other ER/PR combinations[12]. rs10995201 was the only variant found in case-case comparisons to be solely associated with HER2 status, although the evidence was not strong, requiring further confirmation. Previously, rs10995201 showed no evidence of being associated with ER status[37]. Most variants associated with PR or HER2, had not been

investigated for PR or HER2 heterogeneity while adjusting for ER[9–13]. We previously reported rs10941679 to be associated with PR-status, independent of ER, and also with grade[10]. We also found suggestive evidence of PR-specific heterogeneity for 16q12-rs3803662[13], which is in high LD ($r^2=0.78$) with rs4784227 (*TOX3*), a variant strongly associated with PR status. Our findings for rs2747652 are also consistent with a prior BCAC fine-mapping analysis across the *ESR1* locus, which found rs2747652 to be associated with risk of the HER2-positive/non-luminal subtype and high grade independent of ER[9]. rs2747652 overlaps an enhancer region and is associated with reduced *ESR1* and *CCDC170* expression[9].

Histologic grade is a composite of multiple tumor characteristics, including mitotic count, nuclear pleomorphism, and degree of tubule or gland formation, therefore susceptibility variants associated with tumor grade could affect multiple biological pathways [38]. Evidence from comparisons of tumor morphology and genomic and molecular alterations suggest that tumor grade is likely a ‘stable’ tumor feature and does not progress from low- to high-grade [39–42], thus the variants associated with grade are likely not associated with grade progression. Among the 12 variants identified with evidence of heterogeneity by grade only, rs17426269, rs11820646, and rs11571833 were most strongly associated with risk of grade 3 disease. rs11571833 lies in the *BRCA2* coding region and produces a truncated form of the protein[43] and has been shown to be associated with both risk of TN disease and risk of serous ovarian tumors, both of which tend to be high-grade[44]. To our knowledge, rs17426269 and rs11820646 have not been investigated in relation to grade heterogeneity. The remaining nine variants were all more strongly associated with grade 1 or grade 2 disease. Six of these variants were previously reported to be associated primarily with ER-positive disease[6, 36, 45, 46], highlighting the importance of accounting for multiple tumor characteristics to better illuminate heterogeneity sources.

We identified 18 variants with evidence of global heterogeneity ($FDR < 5\%$), but no significant (marker-specific $p < 0.05$) associations with any of the individual tumor characteristic(s). This is likely explained by the fact that the test for association with specific tumor markers using fixed-effects models is less powerful than mixed-effects models used to test the primary hypothesis of global heterogeneity by any tumor marker[14].

To help describe and visualize the strength of the evidence for common heterogeneity patterns, we performed clustered analyses of z-values for tumor marker-specific heterogeneity tests and case–control associations with risk of intrinsic-like subtypes. Because they are based on

z-values, these clusters reflect differences in sample size and statistical power to detect associations between variants and specific tumor subtypes. Thus, clusters should not be interpreted as strictly defined categories.

A major strength of our study is our large sample size of over 100,000 breast cancer cases with tumor marker information, and a similar number of controls, making this the largest, most comprehensive breast cancer heterogeneity investigation. Our application of the two-stage polytomous logistic regression enabled adjusting for multiple, correlated tumor markers and accounting for missing tumor marker data. This is a more powerful and efficient modeling strategy for identifying heterogeneity sources among highly correlated tumor markers, compared with standard polytomous logistic regression [14, 15]. In simulated and real data analyses, we have demonstrated that in the presence of heterogeneous associations across subtypes, the two-stage model is more powerful than polytomous logistic regression for detecting heterogeneity. Moreover, we have demonstrated that in the presence of correlated markers, the two-stage model, incorporating all markers simultaneously, has a much better ability to distinguish the true source(s) of heterogeneity than testing for heterogeneity by analyzing one marker at a time [14, 15]. In prior analyses, we showed that the two-stage polytomous regression is a powerful approach to identify susceptibility variants that display tumor heterogeneity [15]. Notably, in this prior investigation we excluded the genomic regions in which the 173 variants that were investigated in this work are located [15].

Our study also has some limitations. First, many breast cancer cases from studies included in this report had missing information on one or more tumor characteristics. ER tumor status data was available for 81% of cases, but missing data for the other tumor markers ranged from 27 to 46%. To address this limitation, we implemented an EM algorithm that allowed a powerful analysis to incorporate cases with missing tumor characteristics under the assumption that tumor characteristics are *missing at random* (MAR), i.e., the underlying reason for missing data may depend on observed tumor markers or/and covariate values, but not on the missing values themselves [47]. If this assumption is violated it can lead to an inflated type-one error [14]. However, in the context of genetic association testing, the missingness mechanism would also need to be related to the genetic variants under study, which is unlikely. The 88 variants that did not meet the p-value threshold for significant heterogeneity in the global test, are likely to represent a combination of variants that are associated with risk of all investigated tumor subtypes with similar effects and variants for which we lacked power to detect evidence of

global heterogeneity due to weak effect sizes or uncommon allele frequencies. In addition, our study focused on investigating ER, PR, HER2, and grade as heterogeneity sources; future studies with more detailed tumor characterization could reveal additional etiologic heterogeneity sources.

Conclusion

Our findings provide insights into the complex etiologic heterogeneity patterns of common breast cancer susceptibility loci. These findings may inform future studies, such as fine-mapping and functional analyses to identify the underlying causal variants, clarifying biological mechanisms that drive genetic predisposition to breast cancer subtypes. Moreover, these analyses provide precise relative risk estimates for different intrinsic-like subtypes that could improve the discriminatory accuracy of subtype-specific polygenic risk scores [48].

Abbreviations

GWAS: Genome-wide association studies; ER: Estrogen receptor; PR: Progesterone receptor; HER2: Human epidermal growth factor receptor 2; SNPs: Single nucleotide polymorphisms; FDR: False discovery rate; TN: Triple-negative; BCAC: Breast Cancer Association Consortium; EM: Expectation–maximization; OR: Odds ratios; 95% CI: 95% Confidence interval; LD: Linkage disequilibrium.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13058-021-01484-x>.

Additional file 1. Figures S1 and S2 and Table S1–S4. This file contains supplementary figures 1–2 and supplementary tables 1–4.

Additional file 2. Figures S3 and S4. This file contains supplementary figures S3 and S4.

Additional file 3. Methods. This file contains the supplementary methods.

Additional file 4. Funding and Acknowledgement. This file contains the additional funding not included in the main text, the acknowledgments, and the names of the people in the collaboration groups.

Acknowledgements

A full description of the acknowledgments is provided in the Additional file 4: Funding and Acknowledgement. NBCS Collaborators: greal@rr-research.no. ABCTB Investigators: mythily.sachchithananthan@sydney.edu.au. kConFab/AOCS Investigators: heather.thorne@petermac.org

Authors' contributions

Writing group: TUA, HZ, KMI, RLM, FJC, JSi, PKr, DFE, PDPP, MKS, MG-C, NCh; Statistical analysis: HZ, TUA, MG-C, NCh; Provision of DNA samples and/or phenotypic data: KMI, RLM, MKB, JDen, AMD, MLus, QW, ILA, HA-C, VA, KJA, PLA, AAu, AB, HBec, SBe, JBen, MBerm, CBl, SEB, BBon, A-LB-BD, HBra, HBre, AB-W, TB, BBur, SSB, FC, JEC, JC-C, SJC, GC-T, CLC, NBCS, JMC, ACox, SSC, KCz, MBD, PD, TD, MDw, DME, DGE, PAF, JFi, GFJ, MG-D, SMG, JAG-S, MMG, GGG, MSG, AG-N, GIG, MGrip, PGU, CAH, PHall, UH, EFH, BAMH-G, BHo, AHol, MJH, RNH, JLHo, AHow, ABCTB, kConFab/AOCS, MJa, AJak, EMJ, MEJ, AJu, Rka, SKaup, RKe, EKh, CMKi, Y-DK, SKou, VNK, UK, KK-S, AWK, KKy, DLd, DGL, ALin, MLin, JLiS, AL, W-LI, RJM, AMan, MMan, SMar, MEM, CMC, AMe, UMe, HNe, WGN, JNo, KOf, HO, NO, T-WP-S, AVP, JPet, GPi, DPK, RP, KPu, KPv, PRa, GR, ARo, TRü, ES, SS, DPS, EJS, RKS, MJS, BSch, MES, X-OS, SSm, MCS, JJS, AJU, RMT, WJT, JAT, LRT, MBT, DT,

MAT, CMV, CHMVD, EMV, PWA, CRW, CWe, JWe, RWi, AW, XRY, WZ, FJC, JSi, PKr, DFE, PDPP, MKS, MG-C. All authors read and approved the final version of the manuscript.

Funding

Open Access funding provided by the National Institutes of Health (NIH). This project has been funded in part with Federal funds from the National Cancer Institute Intramural Research Program, National Institutes of Health. Dr. Nilanjan Chatterjee was supported by NHGRI (1R01 HG010480-01). Dr. Haoyu Zhang was supported by National Cancer Institute (1K99 CA256513). OncoArray genotyping was funded by the government of Canada through Genome Canada and the Canadian Institutes of Health Research (GPH-129344), the Ministère de l'Économie, de la Science et de l'Innovation du Québec through Génome Québec, the Quebec Breast Cancer Foundation for the PERSPECTIVE project, the US National Institutes of Health (NIH) (1 U19 CA 148065 for the Discovery, Biology and Risk of Inherited Variants in Breast Cancer (DRIVE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract HHSN268201200008I), Cancer Research UK (C1287/A16563), the Odense University Hospital Research Foundation (Denmark), the National R&D Program for Cancer Control—Ministry of Health and Welfare (Republic of Korea) (1420190), the Italian Association for Cancer Research (AIRC; IG16933), the Breast Cancer Research Foundation, the National Health and Medical Research Council (Australia) and German Cancer Aid (110837). ICOGS genotyping was funded by the European Union (HEALTH-F2-2009-223175), Cancer Research UK (C1287/A10710, C1287/A10118 and C12292/A11174), NIH grants (CA128978, CA116167 and CA176785) and the Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 (GAME-ON initiative)), an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, the Ministère de l'Économie, Innovation et Exportation du Québec (PSR-SIRI-701), the Komen Foundation for the Cure, the Breast Cancer Research Foundation and the Ovarian Cancer Research Fund. A full description of the funding is provided in the Additional file 4: Funding and Acknowledgement.

Availability of data and materials

The datasets generated and/or analyzed during the current study are part of the Breast Cancer Association Consortium and would be available with the appropriate permissions, including an application process and appropriate data transfer agreements.

Declarations

Ethics approval and consent to participate

All the studies included in these analyses were approved by local IRBs.

Consent for publication

Not applicable.

Competing interests

The authors have no competing interests to declare.

Author details

¹Division of Cancer Epidemiology and Genetics Department of Health and Human Services, Medical Center Drive, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. ²Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. ³Institute of Neurology & Genetics, Biostatistics Unit, Nicosia, Cyprus. ⁴Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. ⁵Cyprus School of Molecular Medicine, Institute of Neurology & Genetics, Nicosia, Cyprus. ⁶Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia. ⁷Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia. ⁸Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia. ⁹Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK. ¹⁰Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada. ¹¹Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada. ¹²Department

of Medicine, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA. ¹³Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. ¹⁴Department of Public Health Sciences, and Cancer Research Institute, Queen's University, Kingston, ON, Canada. ¹⁵Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ¹⁶Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI, USA. ¹⁷Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden. ¹⁸Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. ¹⁹Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ²⁰Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. ²¹Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. ²²Biomedical Network On Rare Diseases (CIBERER), Madrid, Spain. ²³Institute of the Chemistry and Genetics, Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia. ²⁴Saint Petersburg State University, Saint-Petersburg, Russia. ²⁵Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. ²⁶Department of Oncology, Örebro University Hospital, Örebro, Sweden. ²⁷Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ²⁸Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark. ²⁹Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark. ³⁰Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, Milan, Italy. ³¹Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. ³²Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. ³³Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany. ³⁴iFIT-Cluster of Excellence, University of Tübingen, Tübingen, Germany. ³⁵German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany. ³⁶German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. ³⁷Division of Preventive Oncology, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Heidelberg, Germany. ³⁸Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada. ³⁹Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada. ⁴⁰Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute, Ruhr University Bochum (IPA), Bochum, Germany. ⁴¹Molecular Epidemiology Group, German Cancer Research Center (DKFZ), C080 Heidelberg, Germany. ⁴²Molecular Biology of Breast Cancer, University Womens Clinic Heidelberg, University of Heidelberg, Heidelberg, Germany. ⁴³Department of Medicine, Huntsman Cancer Institute, Salt Lake City, UT, USA. ⁴⁴Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany. ⁴⁵Oncology and Genetics Unit, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Xerencia de Xestión Integrada de Vigo-SERGAS, Vigo, Spain. ⁴⁶Cancer Epidemiology Group, University Cancer Center Hamburg (UCC), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ⁴⁷Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. ⁴⁸Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, Australia. ⁴⁹Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands. ⁵⁰Department of Oncology and Metabolism, Sheffield Institute for Nucleic Acids (SiNFA), University of Sheffield, Sheffield, UK. ⁵¹Department of Neuroscience, Academic Unit of Pathology, University of Sheffield, Sheffield, UK. ⁵²Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ⁵³Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA. ⁵⁴Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. ⁵⁵Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. ⁵⁶Gynaecology Research Unit, Hannover Medical School, Hannover, Germany. ⁵⁷School of Life Sciences, University of Westminster, London, UK. ⁵⁸Faculty of Medicine, University of Southampton, Southampton, UK. ⁵⁹North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. ⁶⁰Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK. ⁶¹Department of Gynecology and Obstetrics Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University

Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.

⁶²Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK. ⁶³Cancer Research UK Edinburgh Centre, The University of Edinburgh, Edinburgh, UK. ⁶⁴Fundación Pública Galega de Medicina Xenómica, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain. ⁶⁵Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. ⁶⁶Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, GA, USA. ⁶⁷Medical Oncology Department, Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain. ⁶⁸Division of Clinical Epidemiology, Royal Victoria Hospital, McGill University, Montréal, QC, Canada. ⁶⁹Department of Medicine, McGill University, Montréal, QC, Canada. ⁷⁰Department of Surgery, Oulu University Hospital, University of Oulu, Oulu, Finland. ⁷¹Center for Research in Epidemiology and Population Health (CESP), Team Exposome and Heredity, INSERM, University Paris-Saclay, Villejuif, France. ⁷²Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. ⁷³Department of Oncology, Södersjukhuset, Stockholm, Sweden. ⁷⁴Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. ⁷⁵Division of Informatics, Imaging and Data Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK. ⁷⁶Nightingale & Genesis Prevention Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK. ⁷⁷NHR Manchester Biomedical Research Unit, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. ⁷⁸Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. ⁷⁹Saarland Cancer Registry, Saarbrücken, Germany. ⁸⁰Division of Cancer Sciences, University of Manchester, Manchester, UK. ⁸¹Research Centre for Genetic Engineering and Biotechnology "Georgi D. Efremov", MASA, Skopje, Republic of North Macedonia. ⁸²Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. ⁸³Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland. ⁸⁴Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, USA. ⁸⁵Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. ⁸⁶Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK. ⁸⁷Department of Pathology, Oulu University Hospital, University of Oulu, Oulu, Finland. ⁸⁸Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands. ⁸⁹Department of Genetics and Fundamental Medicine, Bashkir State University, Ufa, Russia. ⁹⁰Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. ⁹¹Department of Internal Medicine, Johanner Kliniken Bonn, Johanner Krankenhaus, Bonn, Germany. ⁹²Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway. ⁹³Department of Histopathology and Cytology, Clinical Hospital Acibadem Sistina, Skopje, Republic of North Macedonia. ⁹⁴Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus. ⁹⁵Laboratory for Translational Genetics, Department of Human Genetics, University of Leuven, Leuven, Belgium. ⁹⁶VIB Center for Cancer Biology, Leuven, Belgium. ⁹⁷Cancer Control Research, BC Cancer, Vancouver, BC, Canada. ⁹⁸Department of Mathematics and Statistics, St. Francis Xavier University, Antigonish, NS, Canada. ⁹⁹Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. ¹⁰⁰Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden. ¹⁰¹Department of Cancer Epidemiology and Prevention, M. Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland. ¹⁰²General and Gastroenterology Surgery Service, Hospital Universitario Central de Asturias, Oviedo, Spain. ¹⁰³University of Tübingen, Tübingen, Germany. ¹⁰⁴Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland. ¹⁰⁵Translational Cancer Research Area, University of Eastern Finland, Kuopio, Finland. ¹⁰⁶Biobank of Eastern Finland, Kuopio University Hospital, Kuopio, Finland. ¹⁰⁷Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset Stockholm, Sweden. ¹⁰⁸Anatomical Pathology, The Alfred Hospital, Melbourne, VIC, Australia. ¹⁰⁹Department of Gynecology and Obstetrics, University of Munich, Campus Großhadern, Munich, Germany. ¹¹⁰Institute of Clinical Trials & Methodology, University College London, London, UK. ¹¹¹Department of Obstetrics and Gynecology, Helsinki University Hospital,

University of Helsinki, Helsinki, Finland. ¹¹²Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA. ¹¹³Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ¹¹⁴Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Ireland, UK. ¹¹⁵Department of Non-Communicable Disease Epidemiology, School of Hygiene and Tropical Medicine, London, UK. ¹¹⁶Human Genotyping-CEGEN Unit, Human Cancer Genetic Program, Spanish National Cancer Research Centre, Madrid, Spain. ¹¹⁷Department of General Medical Oncology and Multidisciplinary Breast Center, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. ¹¹⁸Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, University of Oulu, Biocenter Oulu, Oulu, Finland. ¹¹⁹Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory Centre Oulu, Oulu, Finland. ¹²⁰Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori (INT), Milan, Italy. ¹²¹Technion Faculty of Medicine, Clalit National Cancer Control Center, Carmel Medical Center, Haifa, Israel. ¹²²Medical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain. ¹²³Institute of Pathology, Staedisches Klinikum Karlsruhe, Karlsruhe, Germany. ¹²⁴Department of Oncology, University Hospital of Larissa, Larissa, Greece. ¹²⁵Prevent Breast Cancer Centre and Nightingale Breast Screening Centre, Manchester University NHS Foundation Trust, Manchester, UK. ¹²⁶Epidemiology Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA. ¹²⁷School of Cancer & Pharmaceutical Sciences, Comprehensive Cancer Centre, Guy's Campus, King's College London, London, UK. ¹²⁸Center for Integrated Oncology (CIO), Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. ¹²⁹Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. ¹³⁰Center for Familial Breast and Ovarian Cancer, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. ¹³¹Network Aging Research, University of Heidelberg, Heidelberg, Germany. ¹³²Department of Health Sciences Research, Mayo Clinic College of Medicine, Jacksonville, FL, USA. ¹³³Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA. ¹³⁴Medical Faculty, Ss. Cyril and Methodius University in Skopje, University Clinic of Radiotherapy and Oncology, Skopje, Republic of North Macedonia. ¹³⁵Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC, Australia. ¹³⁶Population Oncology, BC Cancer, Vancouver, BC, Canada. ¹³⁷School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada. ¹³⁸Division of Breast Cancer Research, The Institute of Cancer Research, London, UK. ¹³⁹Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA. ¹⁴⁰Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA. ¹⁴¹Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. ¹⁴²Institute of Human Genetics, Pontificia Universidad Javeriana, Bogotá, Colombia. ¹⁴³Department of Epidemiology, Gillings School of Global Public Health and UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ¹⁴⁴Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA. ¹⁴⁵Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands. ¹⁴⁶Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA. ¹⁴⁷Department of Pathology, The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands. ¹⁴⁸Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. ¹⁴⁹Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. ¹⁵⁰Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. ¹⁵¹Genomics Center, Department of Molecular Medicine, Centre Hospitalier Universitaire de Québec, Université Laval Research Center, Université Laval, Québec City, QC, Canada. ¹⁵²Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. ¹⁵³Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. ¹⁵⁴Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands. ¹⁵⁵Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. ¹⁵⁶Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. ¹⁵⁷Department of Research, Vestre Viken Hospital,

Drammen, Norway. ¹⁵⁸Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. ¹⁵⁹Section for Breast- and Endocrine Surgery, Department of Cancer, Division of Surgery, Cancer and Transplantation Medicine, Oslo University Hospital-Ullevål, Oslo, Norway. ¹⁶⁰Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway. ¹⁶¹Department of Pathology, Akershus University Hospital, Lørenskog, Norway. ¹⁶²Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. ¹⁶³Department of Oncology, Division of Surgery and Cancer and Transplantation Medicine, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. ¹⁶⁴National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology, Oslo University Hospital, Oslo, Norway. ¹⁶⁵Department of Oncology, Akershus University Hospital, Lørenskog, Norway. ¹⁶⁶OSBREAC (Breast Cancer Research Consortium (Chair: Kristine K. Sahlberg), Oslo University Hospital, Oslo, Norway. ¹⁶⁷Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, Australia. ¹⁶⁸Pathology West ICPMR, Westmead, NSW, Australia. ¹⁶⁹Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, Sydney, NSW, Australia. ¹⁷⁰Pathology North, John Hunter Hospital, Newcastle, NSW 2305, Australia. ¹⁷¹Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, Australia. ¹⁷²Department of Anatomical Pathology, ACT Pathology, Canberra Hospital, Canberra, ACT, Australia. ¹⁷³ANU Medical School, Australian National University, Canberra, ACT, Australia. ¹⁷⁴Department of Surgical Oncology, Calvary Mater Newcastle Hospital, Australian New Zealand Breast Cancer Trials Group, and School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia. ¹⁷⁵School of Science and Health, The University of Western Sydney, Sydney, Australia. ¹⁷⁶Hormones and Cancer Group, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Newcastle, NSW, Australia. ¹⁷⁷SydPath St Vincent's Hospital, Sydney, NSW, Australia. ¹⁷⁸Department of Tissue Pathology and Diagnostic Oncology, Pathology West, Westmead Breast Cancer Institute, Westmead Hospital, Westmead, NSW, Australia. ¹⁷⁹Centre for Information Based Medicine, Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia. ¹⁸⁰Priority Research Centre for Cancer, School of Biomedical Sciences and Pharmacy, Faculty of Health, University of Newcastle, Newcastle, NSW, Australia. ¹⁸¹The University of Queensland: UQ Centre for Clinical Research and School of Medicine, Brisbane, QLD, Australia. ¹⁸²Hereditary Cancer Clinic, St Vincent's Hospital, The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia. ¹⁸³Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, Australia. ¹⁸⁴Sydney Medical School - Westmead, University of Sydney, Sydney, NSW, Australia. ¹⁸⁵Department of Medical Oncology, The Canberra Hospital, Canberra, ACT, Australia. ¹⁸⁶St John of God Perth Northern Hospitals, Perth, WA, Australia. ¹⁸⁷Peter MacCallum Cancer Centre, Melbourne, Australia. ¹⁸⁸QIMR Berghofer Medical Research Institute, Brisbane, Australia. ¹⁸⁹Westmead Institute for Medical Research, Sydney, Australia. ¹⁹⁰BCNA delegate, Community Representative, Melbourne, Australia. ¹⁹¹Westmead Hospital, Sydney, Australia. ¹⁹²Walter and Eliza Hall Institute, Melbourne, Australia. ¹⁹³University of Sydney, Sydney, Australia. ¹⁹⁴University of Melbourne, Melbourne, Australia. ¹⁹⁵Cancer Council Victoria, Melbourne, Australia. ¹⁹⁶Melbourne Health, Melbourne, Australia.

Received: 15 June 2021 Accepted: 2 November 2021
Published online: 04 January 2022

References

1. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. *Nature*. 2012;490(7418):61–70.
2. Curigliano G, Burstein HJ, Gnant M, Dubsy P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ et al. De-escalating and escalating treatments for early-stage breast cancer: the St Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol* 2017, 28(8):1700–1712.
3. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ. Panel m: personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. *Ann Oncol*. 2013;24(9):2206–23.
4. Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. *Biochim Biophys Acta*. 2015;1856(1):73–85.
5. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. *J Natl Cancer Inst*. 2011;103(3):250–63.
6. Michailidou K, Lindstrom S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A, Soucy P, Glubb D, Rostamianfar A, et al. Association analysis identifies 65 new breast cancer risk loci. *Nature*. 2017;551(7678):92–4.
7. Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindstrom S, Hui S, Lemaçon A, Soucy P, Dennis J, et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nat Genet*. 2017;49(12):1767–78.
8. García-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, Orr N, Rhie SK, Riboli E, Feigelson HS, et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. *Nat Genet*. 2013;45(4):392–8.
9. Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, et al. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nat Genet*. 2011;43(4):374–86.
10. Milne RL, Goode EL, García-Closas M, Couch FJ, Severi G, Hein R, Fredericksen Z, Malats N, Zamora MP, Arias Perez JJ, et al. Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. *Cancer Epidemiol Biomark Prevent*. 2011;20(10):2222–31.
11. Figueroa JD, García-Closas M, Humphreys M, Platte R, Hopper JL, Southey MC, Apicella C, Hammet F, Schmidt MK, Broeks A, et al. Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. *Hum Mol Genet*. 2011;20(23):4693–706.
12. Orr N, Dudbridge F, Dryden N, Maguire S, Novo D, Perrakis E, Johnson N, Ghoussaini M, Hopper JL, Southey MC, et al. Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. *Hum Mol Genet*. 2015;24(10):2966–84.
13. Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, Apicella C, Smith LD, Hammet F, Southey MC, et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. *Hum Mol Genet*. 2011;20(16):3289–303.
14. Zhang H, Zhao N, Ahearn TU, Wheeler W, García-Closas M, Chatterjee N: A mixed-model approach for powerful testing of genetic associations with cancer risk incorporating tumor characteristics. *Biostatistics* 2020.
15. Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, Jiang X, O'Mara TA, Zhao N, Bolla MK, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nat Genet*. 2020;52(6):572–81.
16. Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, Turman C, et al. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nat Genet*. 2020;52(1):56–73.
17. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via em algorithm. *J Roy Stat Soc B Met*. 1977;39(1):1–38.
18. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J Roy Stat Soc: Ser B (Methodol)*. 1995;57(1):289–300.
19. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics*. 2016;32(18):2847–9.
20. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Breast cancer statistics, 2019. *CA Cancer J Clin*. 2019;69(6):438–51.
21. Mesa-Eguiaagaray I, Wild SH, Rosenberg PS, Bird SM, Brewster DH, Hall PS, Cameron DA, Morrison D, Figueroa JD. Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data. *Br J Cancer*. 2020;123(5):852–9.
22. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struwing JP, Morrison J, Field H, Luben R, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature*. 2007;447(7148):1087–93.
23. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, et al. A genome-wide association

- study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. *Nat Genet.* 2007;39(7):870–4.
24. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, Masson G, Jakobsdottir M, Thorlacius S, Helgason A, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat Genet.* 2007;39(7):865–9.
 25. Li J, Williams BL, Haire LF, Goldberg M, Wilker E, Durocher D, Yaffe MB, Jackson SP, Smerdon SJ. Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. *Mol Cell.* 2002;9(5):1045–54.
 26. McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, Caporaso NE, Johansson M, Xiao X, Li Y, et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. *Nat Genet.* 2017;49(7):1126–32.
 27. Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, Zong X, Laplana M, Wei Y, Han Y, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. *Nat Genet.* 2014;46(7):736–41.
 28. Obazee O, Archibugi L, Andriulli A, Soucek P, Malecka-Panas E, Ivanauskas A, Johnson T, Gazouli M, Pausch T, Lawlor RT, et al. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. *Int J Cancer.* 2019;145(3):686–93.
 29. Rudd MF, Sellick GS, Webb EL, Catovsky D, Houlston RS. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. *Blood.* 2006;108(2):638–44.
 30. Liu C, Wang QS, Wang YJ. The CHEK2 I157T variant and colorectal cancer susceptibility: a systematic review and meta-analysis. *Asian Pac J Cancer Prev.* 2012;13(5):2051–5.
 31. Lesseur C, Ferreiro-Iglesias A, McKay JD, Bosse Y, Johansson M, Gaborieau V, Landi MT, Christiani DC, Caporaso NC, Bojesen SE et al. Genome-wide association meta-analysis identifies pleiotropic risk loci for aerodigestive squamous cell cancers. *PLoS genetics* 2021, 17(3):e1009254.
 32. Ovarian Cancer Association Consortium - Results lookup by region [<http://ocac.ccge.medschl.cam.ac.uk/data-projects/results-lookup-by-region/>]
 33. Fang J, Jia J, Makowski M, Xu M, Wang Z, Zhang T, Hoskins JW, Choi J, Han Y, Zhang M, et al. Functional characterization of a multi-cancer risk locus on chr5p1533 reveals regulation of TERT by ZNF148. *Nat Commun.* 2017;8(1):15034.
 34. Kim-Hellmuth S, Aguet F, Oliva M, Munoz-Aguirre M, Kasela S, Wucher V, Castel SE, Hamel AR, Vinuela A, Roberts AL et al. Cell type-specific genetic regulation of gene expression across human tissues. *Science* 2020, 369(6509).
 35. Li X, Zou W, Liu M, Cao W, Jiang Y, An G, Wang Y, Huang S, Zhao X. Association of multiple genetic variants with breast cancer susceptibility in the Han Chinese population. *Oncotarget.* 2016;7(51):85483–91.
 36. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nat Genet.* 2013;45(4):353–61.
 37. Darabi H, McCue K, Beesley J, Michailidou K, Nord S, Kar S, Humphreys K, Thompson D, Ghoussaini M, Bolla MK, et al. Polymorphisms in a putative enhancer at the 10q21.2 breast cancer risk locus regulate NRBF2 expression. *Am J Hum Genet.* 2015;97(1):22–34.
 38. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology.* 1991;19(5):403–10.
 39. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. *J Pathol.* 2011;223(2):307–17.
 40. Schymik B, Buerger H, Kramer A, Voss U, van der Groep P, Meinerz W, van Diest PJ, Korsching E. Is there “progression through grade” in ductal invasive breast cancer? *Breast Cancer Res Treat.* 2012;135(3):693–703.
 41. Roylance R, Gorman P, Harris W, Liebmann R, Barnes D, Hanby A, Sheer D. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. *Can Res.* 1999;59(7):1433–6.
 42. Rajakari R, Walker RA. Pathological and biological features of mammographically detected invasive breast carcinomas. *Br J Cancer.* 1995;71(1):150–4.
 43. Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS, Gayther SA, Mangion J, Stratton MR, Lynch HT, et al. A polymorphic stop codon in BRCA2. *Nat Genet.* 1996;14(3):253–4.
 44. Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, McGuffog L, Ellis S et al. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *J Natl Cancer Inst* 2016, 108(2).
 45. Darabi H, Beesley J, Droit A, Kar S, Nord S, Moradi Marjaneh M, Soucy P, Michailidou K, Ghoussaini M, Fues Wahl H, et al. Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGS). *Sci Rep.* 2016;6:32512.
 46. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, Maranian MJ, Bolla MK, Wang Q, Shah M, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nat Genet.* 2015;47(4):373–80.
 47. Little RJA, Rubin DB. Statistical analysis with missing data. In: *Wiley series in probability and statistics*. Third edition edn. Hoboken, NJ: Wiley; 2019: 1 online resource.
 48. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *Am J Hum Genet.* 2019;104(1):21–34.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions